ATG7 Knockout HEK293 Cell Line
Cat.No.:
EDC90151
Species:
Human
Cell Name:
HEK293
Gene:
ATG7
Gene ID:
10533
Size:
1×10⁶cells
ATG7 Knockout Cell Line (HEK293) is an exclusive upgraded CRISPR/Cas9 system-mediated gene knockout cell, with the advantages of Optimized Strategy Design, Efficient Cell Transfection, High-Performance Cas9 Protein and Hassle-Free Cell Selection.
| Cat.No. | EDC90151 |
|---|---|
| Product Name | ATG7 Knockout Cell Line (HEK293) |
| Cell Line | HEK293 |
| Cellosaurus ID | CVCL_0045 |
| Cell Line Synonyms | Hek293, HEK-293, HEK/293, (HEK)293, HEK 293, HEK,293, 293, 293 HEK, 293 Ad5, Graham 293, Graham-293, Human Embryonic Kidney 293 |
| Gene | ATG7 |
| NCBI Gene ID | |
| Gene Synonyms | APG7-LIKE|APG7L|GSA7|SCAR31 |
| Summary |
This gene encodes an E1-like activating enzyme that is essential for autophagy and cytoplasmic to vacuole transport. The encoded protein is also thought to modulate p53-dependent cell cycle pathways during prolonged metabolic stress. It has been associated with multiple functions, including axon membrane trafficking, axonal homeostasis, mitophagy, adipose differentiation, and hematopoietic stem cell maintenance. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2015]
|
| Associated Diseases | Non-tumor |
| Morphology | Adherent |
| Passage Ratio | 1/5,2days |
| Complete Culture Medium | DMEM + 10% FBS |
| Freezing Medium | 95% Complete culture medium+ 5% DMSO |
| QC | Indels validated by Sanger sequencing; sterility confirmed via microbial testing. |
* For research use only. Not intended for use in humans or animals, including clinical, therapeutic, or diagnostic purposes.
| Loci | STR Info (Sample Cell) Sample Cell Line: HEK293 | STR Info (Cell bank) Cell Line: HEK293 | ||
| Allele1 | Allele2 | Allele1 | Allele2 | |
| Amelogenin | X | X | ||
| CSF1P0 | 12 | 11 | 12 | |
| D2S1338 | 19 | 19 | ||
| D3S1358 | 15 | 17 | 15 | 17 |
| D5S818 | 8 | 8 | 9 | |
| D7S820 | 11 | 12 | 11 | 12 |
| D8S1179 | 12 | 14 | 12 | 14 |
| D13S317 | 12 | 14 | 12 | 14 |
| D16S539 | 9 | 13 | 9 | 13 |
| D18S51 | 17 | 18 | 17 | 18 |
| D19S433 | 15 | 18 | 15 | 18 |
| D21S11 | 28 | 30.2 | 28 | 30.2 |
| FGA | 23 | 23 | ||
| Penta D | 9 | 10 | 9 | 10 |
| Penta E | 7 | 15 | 7 | 15 |
| TH01 | 7 | 9.3 | 7 | 9.3 |
| TPOX | 11 | 11 | ||
| vWA | 16 | 19 | 16 | 19 |
| D6S1043 | 11 | 11 | ||
| D12S391 | 19 | 21 | 11 | 15 |
| D2S441 | 11 | 15 | 11 | 15 |
* STR authentication data of this cell line matches with that of cell lines sourced from ATCC, DSMZ, JCRB, and RIKEN databases.
Conclusion: The STR identification of this cell is correct.
Conclusion: The STR identification of this cell is correct.
FAQ
Which is better for studying ATG7 function, ATG7 Knockout HEK293 Cell Line or ATG7 overexpression HEK293 Cell Line?
The choice depends on whether you are studying ATG7's role as the essential E1-like enzyme for autophagy or modeling autophagy deficiency in mammalian cells. The Knockout line is the standard tool for asking whether ATG7 is required for canonical autophagy — ATG7 is a ubiquitin-activating (E1)-like enzyme that activates two ubiquitin-like proteins: ATG12 (conjugated to ATG5) and LC3/GABARAP family members (lipidated to phosphatidylethanolamine, generating LC3-II); ATG7 activity is absolutely essential for canonical autophagy. Overexpression is useful for studying ATG7 gain-of-function effects.
For autophagy research, the EDITGENE ATG7 Knockout in HEK293 is the gold-standard autophagy-deficient cell model — ATG7 KO abolishes LC3-II formation, ATG12-ATG5 conjugation, and canonical macroautophagy. This product complements the parallel ATG12 Knockout in HAP1 (also available) for systematic autophagy machinery dissection. Rescue with wild-type or catalytically-dead ATG7 (C572S in the catalytic cysteine) enables structure-function studies. The knockout is valuable for studying autophagy biology, autophagy-dependent vs autophagy-independent cell death, and emerging ATG7-targeted approaches in cancer (autophagy inhibitors like hydroxychloroquine are in clinical development as cancer chemotherapy sensitizers).
What are the application scenarios for this model?
Primary applications:
• Autophagy assays: LC3-I/LC3-II conversion (LC3-II absent in ATG7 KO), p62/SQSTM1 accumulation, autophagosome formation by EM, mt-Keima/Rosella reporter assays.
• Autophagy-dependent processes: mitophagy, ER-phagy, ribophagy analysis given complete autophagy abolition.
• Autophagy inhibitor specificity: critical genetic control for hydroxychloroquine, bafilomycin A1, and emerging autophagy-targeted compounds in cancer chemotherapy sensitization research.
• Selective autophagy: receptor-mediated autophagy pathway dissection.
EDITGENE recommends this HEK293-based model as the gold-standard autophagy-deficient model for systematic autophagy research.
Is this ATG7 Knockout HEK293 Cell Line compatible with overexpression rescue experiments?
Yes. ATG7 rescue experiments are gold-standard for autophagy research:
• Construct design: use a codon-modified ATG7 sequence with a small C-terminal tag (FLAG, HA). ATG7 has N-terminal ATG12-interaction region, central ATP-binding region, and C-terminal LC3-interaction region — preserve all elements.
• Catalytically-dead rescue: C572S mutation in the catalytic cysteine abolishes E1-like activity — gold-standard specificity control.
• Functional readout: rescue should restore LC3-II formation, ATG12-ATG5 conjugation, and autophagic flux measured by LC3 puncta and p62 turnover.
HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.
* Research Use Disclaimer: Content is generated from publicly available research data, bioinformatic resources, and computational analyses for research reference only.
Related Publications
Ablation of endothelial inhibits ischemia-induced angiogenesis by upregulating that suppresses expression.
IF=14.3
Autophagy
Ischemia-induced angiogenesis is critical for blood flow restoration and tissue regeneration, but the underlying molecular mechanism is not fully understood. ATG7 (autophagy related 7) is essential for classical degradative macroautophagy/autophagy and cell cycle regulation. However, whether and how ATG7 influences endothelial cell (EC) function and regulates post-ischemic angiogenesis remain unknown. Here, we showed that in mice subjected to femoral artery ligation, EC-specific deletion of significantly impaired angiogenesis, delayed the recovery of blood flow reperfusion, and displayed reduction in HIF1A (hypoxia inducible factor 1 subunit alpha) expression. In addition, in cultured human umbilical vein endothelial cells (HUVECs), overexpression of prevented deficiency-reduced tube formation. Mechanistically, we identified STAT1 (signal transducer and activator of transcription 1) as a transcription suppressor of and demonstrated that ablation of upregulated STAT1 in an autophagy independent pathway, increased STAT1 binding to promoter, and suppressed expression. Moreover, lack of ATG7 in the cytoplasm disrupted the association between ATG7 and the transcription factor ZNF148/ZFP148/ZBP-89 (zinc finger protein 148) that is required for STAT1 constitutive expression, increased the binding between ZNF148/ZFP148/ZBP-89 and KPNB1 (karyopherin subunit beta 1), which promoted ZNF148/ZFP148/ZBP-89 nuclear translocation, and increased STAT1 expression. Finally, inhibition of STAT1 by fludarabine prevented the inhibition of HIF1A expression, angiogenesis, and blood flow recovery in KO mice. Our work reveals that lack of ATG7 inhibits angiogenesis by suppression of HIF1A expression through upregulation of STAT1 independently of autophagy under ischemic conditions, and suggest new therapeutic strategies for cancer and cardiovascular diseases.: ATG5: autophagy related 5; ATG7: autophagy related 7; KO: endothelial cell-specific knockout; BECN1: beclin 1; ChIP: chromatin immunoprecipitation; CQ: chloroquine; ECs: endothelial cells; EP300: E1A binding protein p300; HEK293: human embryonic kidney 293 cells; HIF1A: hypoxia inducible factor 1 subunit alpha; HUVECs: human umbilical vein endothelial cells; IFNG/IFN-γ: Interferon gamma; IRF9: interferon regulatory factor 9; KPNB1: karyopherin subunit beta 1; MAP1LC3A: microtubule associated protein 1 light chain 3 alpha; MEFs: mouse embryonic fibroblasts; MLECs: mouse lung endothelial cells; NAC: N-acetyl-l-cysteine; NFKB1/NFκB: nuclear factor kappa B subunit 1; PECAM1/CD31: platelet and endothelial cell adhesion molecule 1; RELA/p65: RELA proto-oncogene, NF-kB subunit; ROS: reactive oxygen species; SP1: Sp1 transcription factor; SQSTM1/p62: sequestosome 1; STAT1: signal transducer and activator of transcription 1; ULK1: unc-51 like autophagy activating kinase 1; KO: endothelial cell-specific knockout; VSMCs: mouse aortic smooth muscle cells; WT: wild type; ZNF148/ZFP148/ZBP-89: zinc finger protein 148.
NBR1 mediates autophagic degradation of IRF3 to negatively regulate type I interferon production.
IF=2.2
Biochemical and biophysical research communications
In the setting of virus infection, autophagy regulates the synthesis of type I interferon (IFN) via multiple mechanisms to prevent adverse overreaction. Interferon regulatory factor (IRF) 3, the dominant transcriptional factor of type I IFN, can be degraded via autophagy-lysosomal pathway. However, the exact regulatory mechanism is not yet well elucidated. IRF3 was targeted into autophagosome by interacting with cargo receptors including p62, NDP52 and NBR1. The recent studies have reported the mechanism of p62 and NDP52 sequestrating IRF3. This work aims to investigate the role of NBR1 in the process of IRF3 degradation. We found that blocking autophagy via ATG3/ATG7 knockout and chemical inhibitors both resulted in the accumulation of IRF3 protein and increased synthesis of type I IFN, while enhancing autophagy activity led to more obvious clearance of IRF3 in HEK293T cells infected with Sendai virus (SeV). Our data suggested that NBR1 bound both unphosphorylated and phosphorylated IRF3 through its ubiquitin-associated domain. Meanwhile, viral infection elevated the expression of NBR1, which sequentially formed a negative feedback loop to promote IRF3 degradation and hence optimized the type I IFN signaling. This study expands the knowledge of molecular mechanisms regulating the IRF3 stability and function during viral infection.
This KO model may be useful for:
- Investigating the autophagy-independent role of ATG7 in regulating STAT1 expression and nuclear translocation via ZNF148/KPNB1 interaction
- Studying the suppression of HIF1A expression and its impact on post-ischemic angiogenesis and blood flow recovery
- Modeling the STAT1-mediated transcriptional repression of HIF1A in endothelial cell function
- Evaluating therapeutic strategies for cancer and cardiovascular diseases involving STAT1 inhibition (e.g., fludarabine)
- Analyzing the differential effects of ATG7 on classical autophagy versus cell cycle regulation in hypoxic conditions
download